Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11247MR)

This product GTTS-WQ11247MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11247MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9760MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ4850MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ13551MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ14866MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ7795MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ8845MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ7681MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ2838MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW